GENETIC TECHNOLOGIES LTD
NASDAQ: GENE (Genetic Technologies Ltd)
Last update: yesterday, 11:22AM0.000
0.00 (0.00%)
| Price / Sales | 0.560 |
| Price / Book | 3.29 |
| Profit Margin | -124.24% |
| Operating Margin (TTM) | -113.14% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | -10.60% |
| Total Debt/Equity (MRQ) | 47.81% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | -9.68 M |
| Levered Free Cash Flow (TTM) | -5.72 M |
| Return on Assets (TTM) | -62.93% |
| Return on Equity (TTM) | -184.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Genetic Technologies Ltd | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.63 |
|
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Institutions | 1.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ashton Thomas Securities, Llc | 30 Sep 2024 | 5 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |